Novel cancer antigens for personalized immunotherapies: Latest evidence and clinical potential

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 1, 2016, Pages 4-31

  Wurz, Gregory T ^a   Kao, Chiao Jung ^b   Degregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antitumor antibody; Cancer vaccine; Cancer testis antigen; Immunotherapy; Oncofetal antigen; Tumor associated antigen

Indexed keywords

5T4 SUPERANTIGEN ANTIBODY FUSION PROTEIN; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BMS 936559; CANCER VACCINE; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIOXYGENASE; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; HYBRID PROTEIN; INDOLAMINE 2,3 DIOXYGENASE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONOCLONAL ANTIBODY; MUCIN 1; NECITUMUMAB; NIVOLUMAB; ONCOFETAL ANTIGEN; PANITUMUMAB; PROGRAMMED DEATH 1 RECEPTOR; SURVIVIN; TIM 3; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); COLON CANCER; HEAD AND NECK CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PERSONALIZED IMMUNOTHERAPY; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84951790085     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015615514     Document Type: Review

References (276)

1. Advani A. McDonough S. Coutre S. Wood B. Radich J. Mims M. et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed / refractory acute lymphocytic leukaemia. Br J Haematol 165: 504–509.
2. Agarwal S. Saini S. Parashar D. Verma A. Sinha A. Jagadish N. et al. (2013) The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma. Oncoimmunology 2: e24270.
3. Ai J. Advani A. (2015) Current status of antibody therapy in ALL. Br J Haematol 168: 471–480.
4. Akiyama Y. Komiyama M. Miyata H. Yagoto M. Ashizawa T. Iizuka A. et al. (2014) Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients. Oncol Rep 31: 1683–1690.
5. Alfonso M. Diaz A. Hernandez A. Perez A. Rodriguez E. Bitton R. et al. (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168: 2523–2529.
6. Alfonso S. Valdes-Zayas A. Santiesteban E. Flores Y. Areces F. Hernandez M. et al. (2014) A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 20: 3660–3671.
7. Almeida L. Sakabe N. de Oliveira A. Silva M. Mundstein A. Cohen T. et al. (2009) CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 37: D816–D819.
8. Amato R. Hawkins R. Kaufman H. Thompson J. Tomczak P. Szczylik C. et al. (2010) Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16: 5539–5547.
9. Anderson A. (2014) TIM-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2: 393–398.
10. Anderson M. Venanzi E. Klein L. Chen Z. Berzins S. Turley S. et al. (2002) Projection of an immunological self shadow within the thymus by the Aire protein. Science 298: 1395–1401.
11. Annesley C. Brown P. (2015) Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol 6: 61–79.
12. Apostolopoulos V. McKenzie I. (1994) Cellular mucins: targets for immunotherapy. Crit Rev Immunol 14: 293–309.
13. Arlen P. Skarupa L. Pazdur M. Seetharam M. Tsang K. Grosenbach D. et al. (2007) Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 178: 1515–1520.
14. Armand P. Nagler A. Weller E. Devine S. Avigan D. Chen Y. et al. (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31: 4199–4206.
15. Atkins M. Kudchadkar R. Sznol M. McDermott D. Lotem M. Schachter J. et al. (2014) Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J Clin Oncol 32(Suppl. 5): abstract 9001.
16. Bagarazzi M. Yan J. Morrow M. Shen X. Parker R. Lee J. et al. (2012) Immunotherapy against HPV16/18 generates potent TH 1 and cytotoxic cellular immune responses. Sci Transl Med 4: 155ra138.
17. Bang Y. van Cutsem E. Feyereislova A. Chung H. Shen L. Sawaki A. et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.
18. Beauchemin N. Arabzadeh A. (2013) Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 32: 643–671.
19. Becker J. Andersen M. Hofmeister-Muller V. Wobser M. Frey L. Sandig C. et al. (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 61: 2091–2103.
20. Berger C. Sommermeyer D. Hudecek M. Berger M. Balakrishnan A. Paszkiewicz P. et al. (2015) Safety of targeting ROR 1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res 3: 206–216.
21. Bokemeyer C. Bondarenko I. Makhson A. Hartmann J. Aparicio J. de Braud F. et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663–671.
22. Bokemeyer C. van Cutsem E. Rougier P. Ciardiello F. Heeger S. Schlichting M. et al. (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48: 1466–1475.
23. Bonner J. Harari P. Giralt J. Azarnia N. Shin D. Cohen R. et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578.
24. Boyerinas B. Jochems C. Fantini M. Heery C. Gulley J. Tsang K. et al. (2015) Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3: 1148–1157.
25. Brahmer J. Reckamp K. Baas P. Crino L. Eberhardt W. Poddubskaya E. et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123–135.
26. Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
27. Brayman M. Thathiah A. Carson D. (2004) MUC1: a multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2: 4.
28. Brignone C. Gutierrez M. Mefti F. Brain E. Jarcau R. Cvitkovic F. et al. (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP 321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8: 71.
29. Brun J. Dalstein V. Leveque J. Mathevet P. Raulic P. Baldauf J. et al. (2011) Regression of high-grade cervical intraepithelial neoplasia with TG 4001 targeted immunotherapy. Am J Obstet Gynecol 204: 169.e1–169.e8.
30. Butts C. Socinski M. Mitchell P. Thatcher N. Havel L. Krzakowski M. et al. (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15: 59–68.
31. Buzzonetti A. Fossati M. Catzola V. Scambia G. Fattorossi A. Battaglia A. (2014) Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival - a substudy of the MIMOSA trial. Cancer Immunol Immunother 63: 1037–1045.
32. Calabro L. Ceresoli G. di Pietro A. Cutaia O. Morra A. Ibrahim R. et al. (2015) CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic / target therapy? Cancer Immunol Immunother 64: 105–112.
33. Calabro L. Morra A. Fonsatti E. Cutaia O. Amato G. Giannarelli D. et al. (2013) Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14: 1104–1111.
34. Camisaschi C. de Filippo A. Beretta V. Vergani B. Villa A. Vergani E. et al. (2014) Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J Invest Dermatol 134: 1893–1902.
35. Cha E. Wallin J. Kowanetz M. (2015) PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol 42: 484–487.
36. Cheema Z. Hari-Gupta Y. Kita G. Farrar D. Seddon I. Corr J. et al. (2014) Expression of the cancer-testis antigen BORIS correlates with prostate cancer. Prostate 74: 164–176.
37. Chen F. Lu Z. Deng J. Han X. Bai J. Liu Q. et al. (2014) SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. Oncol Rep 32: 2533–2540.
38. Chen J. Dawoodji A. Tarlton A. Gnjatic S. Tajar A. Karydis I. et al. (2015) NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. Int J Cancer 136: E590–E601.
39. Chen R. Chen B. (2015) Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma. Drug Des Devel Ther 9: 1729–1733.
40. Chen Y. Scanlan M. Sahin U. Tureci O. Gure A. Tsang S. et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94: 1914–1918.
41. Cheng J. Kananathan R. (2012) CIMAvax EGF vaccine for stage IIIb / IV non-small cell lung carcinoma. Hum Vaccin Immunother 8: 1799–1801.
42. Cheng L. Ruan Z. (2015) Tim-3 and Tim-4 as the potential targets for antitumor therapy. Hum Vaccin Immunother 11: 2458–2462.
43. Chung C. (2015) Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. J Oncol Pharm Pract. DOI: 10.1177/1078155215577810.
44. Coosemans A. Vergote I. van Gool S. (2014) Wilms’ tumor gene 1 immunotherapy in pelvic gynecological malignancies. Expert Rev Clin Immunol 10: 705–711.
45. Creelan B. (2014) Update on immune checkpoint inhibitors in lung cancer. Cancer Control 21: 80–89.
46. Cunningham D. Humblet Y. Siena S. Khayat D. Bleiberg H. Santoro A. et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.
47. Curigliano G. Criscitiello C. Esposito A. Fumagalli L. Gelao L. Locatelli M. et al. (2013) Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. Breast 22(Suppl. 2): S96–S99.
48. de Pas T. Giovannini M. Rescigno M. Catania C. Toffalorio F. Spitaleri G. et al. (2012) Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials. Crit Rev Oncol Hematol 83: 432–443.
49. de Gregorio M. Soe L. Wolf M. (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis 6: 571–573.
50. de Gregorio M. Wurz G. Gutierrez A. Wolf M. (2012) L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible? OncoImmunology 1: 1422–1424.
51. Derbinski J. Gabler J. Brors B. Tierling S. Jonnakuty S. Hergenhahn M. et al. (2005) Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels. J Exp Med 202: 33–45.
52. Di Stasi A. Jimenez A. Minagawa K. Al-Obaidi M. Rezvani K. (2015) Review of the results of WT 1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 6: 36.
53. Diaz A. Alfonso M. Alonso R. Saurez G. Troche M. Catala M. et al. (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107: 80–89.
54. Dillman R. (2015) Cancer vaccines: can they improve survival? Cancer Biother Radiopharm 30: 147–151.
55. Di Paola R. Plante M. Kaufman H. Petrylak D. Israeli R. Lattime E. et al. (2006) A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 4: 1.
56. Douillard J. Siena S. Cassidy J. Tabernero J. Burkes R. Barugel M. et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX 4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697–4705.
57. Eisen T. Hedlund G. Forsberg G. Hawkins R. (2014) Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep 16: 370.
58. Elkord E. Burt D. Sundstedt A. Nordle O. Hedlund G. Hawkins R. (2015) Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2 / 3 study of naptumomab estafenatox plus IFN-alpha versus IFN-alpha. Oncotarget 6: 4428–4439.
59. Emens L. Braiteh F. Cassier P. Delord J. Eder J. Fasso M. et al. (2015) Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) (Abstract 2859). In: Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, 18–22 April.
60. Endo M. de Graaff M. Ingram D. Lim S. Lev D. Briaire-de Bruijn I. et al. (2015) NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28: 587–595.
61. Escudier B. Bellmunt J. Negrier S. Bajetta E. Melichar B. Bracarda S. et al. (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144–2150.
62. Escudier B. Pluzanska A. Koralewski P. Ravaud A. Bracarda S. Szczylik C. et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111.
63. Felder M. Kapur A. Gonzalez-Bosquet J. Horibata S. Heintz J. Albrecht R. et al. (2014) MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 13: 129.
64. Ferrara N. Hillan K. Gerber H. Novotny W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391–400.
65. Foley E. (1953) Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13: 835–837.
66. Fourcade J. Sun Z. Pagliano O. Chauvin J. Sander C. Janjic B. et al. (2014) PD-1 and TIM-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res 74: 1045–1055.
67. Friedman H. Prados M. Wen P. Mikkelsen T. Schiff D. Abrey L. et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733–4740.
68. Fuchs C. Tomasek J. Yong C. Dumitru F. Passalacqua R. Goswami C. et al. (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383: 31–39.
69. Galluzzi L. Vacchelli E. Bravo-San Pedro J. Buque A. Senovilla L. Baracco E. et al. (2014) Classification of current anticancer immunotherapies. Oncotarget 5: 12472–12508.
70. Gao X. Zhu Y. Li G. Huang H. Zhang G. Wang F. et al. (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PloS ONE 7: e30676.
71. Garg M. Chaurasiya D. Rana R. Jagadish N. Kanojia D. Dudha N. et al. (2007) Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 13: 1421–1428.
72. Garon E. Ciuleanu T. Arrieta O. Prabhash K. Syrigos K. Goksel T. et al. (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384: 665–673.
73. Garon E. Rizvi N. Hui R. Leighl N. Balmanoukian A. Eder J. et al. (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018–2028.
74. Ghadban T. Perez D. Vashist Y. Bockhorn M. Koenig A. El Gammal A. et al. (2014) Expression of cancer testis antigens CT 10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors. Eur J Surg Oncol 40: 1307–1312.
75. Giantonio B. Catalano P. Meropol N. O'Dwyer P. Mitchell E. Alberts S. et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539–1544.
76. Goldberg M. Drake C. (2011) LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 344: 269–278.
77. Gonzalez G. Crombet T. Neninger E. Viada C. Lage A. (2007) Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 3: 8–13.
78. Gotter J. Brors B. Hergenhahn M. Kyewski B. (2004) Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 199: 155–166.
79. GuhaThakurta D. Sheikh N. Fan L. Kandadi H. Meagher T. Hall S. et al. (2015) Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res 21: 3619–3630.
80. Gulley J. Arlen P. Madan R. Tsang K. Pazdur M. Skarupa L. et al. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59: 663–674.
81. Gulley J. Spigel D. Kelly K. Chandler J. Rajan A. Hassan R. et al. (2015) Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase Ib, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol 33(Suppl.): abstract 8034.
82. Hamid O. Robert C. Daud A. Hodi F. Hwu W. Kefford R. et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369: 134–144.
83. Harrop R. Chu F. Gabrail N. Srinivas S. Blount D. Ferrari A. (2013) Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial. Cancer Immunol Immunother 62: 1511–1520.
84. Harrop R. Shingler W. Kelleher M. de Belin J. Treasure P. (2010) Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother 33: 999–1005.
85. Hay C. Sult E. Huang Q. Hammond S. Mulgrew K. McGlinchey K. et al. (2015) MEDI9447: Enhancing anti-tumor immunity by targeting CD73 in the tumor microenvironment. Cancer Res 75(Suppl. 15): abstract 285.
86. He L. Ji J. Liu S. Xue E. Liang Q. Ma Z. (2014) Expression of cancer-testis antigen in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci 34: 181–185.
87. Heery C. Ibrahim N. Arlen P. Mohebtash M. Murray J. Koenig K. et al. (2015) Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: A randomized clinical trial. JAMA Oncol. DOI: 10.1001/jamaoncol.2015.2736.
88. Herbst R. Soria J. Kowanetz M. Fine G. Hamid O. Gordon M. et al. (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567.
89. Hodi F. Lawrence D. Lezcano C. Wu X. Zhou J. Sasada T. et al. (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2: 632–642.
90. Hodi F. O'Day S. McDermott D. Weber R. Sosman J. Haanen J. et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
91. Hoffman L. Gore L. (2014) Blinatumomab, a bi-specific anti-CD19/CD3 BiTE((R)) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol 4: 63.
92. Hojjat-Farsangi M. Moshfegh A. Daneshmanesh A. Khan A. Mikaelsson E. Osterborg A. et al. (2014) The receptor tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol 29: 21–31.
93. Homet Moreno B. Parisi G. Robert L. Ribas A. (2015) Anti-PD-1 therapy in melanoma. Semin Oncol 42: 466–473.
94. Horn L. Spigel D. Gettinger S. Antonia S. Gordon M. Herbst R. et al. (2015) Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PD-L1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J Clin Oncol 33(Suppl.): abstract 8029.
95. Huang C. Workman C. Flies D. Pan X. Marson A. Zhou G. et al. (2004) Role of LAG-3 in regulatory T cells. Immunity 21: 503–513.
96. Hunder N. Wallen H. Cao J. Hendricks D. Reilly J. Rodmyre R. et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358: 2698–2703.
97. Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.
98. Hynes N. Lane H. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341–354.
99. Ibrahim N. Murray J. Zhou D. Mittendorf E. Sample D. Tautchin M. et al. (2013) Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J Cancer 4: 577–584.
100. Ibrahim R. Stewart R. Shalabi A. (2015) PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol 42: 474–483.
101. Isfort S. Keller-v Amsberg G. Schafhausen P. Koschmieder S. Brummendorf T. (2014) Bosutinib: a novel second-generation tyrosine kinase inhibitor. Recent Results Cancer Res 201: 81–97.
102. Ishikawa H. Imano M. Shiraishi O. Yasuda A. Peng Y. Shinkai M. et al. (2014) Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer 17: 173–180.
103. Iversen T. Andersen M. Svane I. (2015) The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer. Basic Clin Pharmacol Toxicol 116: 19–24.
104. Iversen T. Engell-Noerregaard L. Ellebaek E. Andersen R. Larsen S. Bjoern J. et al. (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20: 221–232.
105. Iwai Y. Ishida M. Tanaka Y. Okazaki T. Honjo T. Minato N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293–12297.
106. Jiang T. Sun Y. Yin Z. Feng S. Sun L. Li Z. (2015) Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Med Chem 7: 185–201.
107. Jing W. Gershan J. Weber J. Tlomak D. McOlash L. Sabatos-Peyton C. et al. (2015) Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer 3: 2.
108. Jonker D. O'Callaghan C. Karapetis C. Zalcberg J. Tu D. Au H. et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040–2048.
109. Jungbluth A. Chen Y. Stockert E. Busam K. Kolb D. Iversen K. et al. (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92: 856–860.
110. Kanojia D. Garg M. Gupta S. Gupta A. Suri A. (2011) Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 178: 1009–1020.
111. Kantoff P. Higano C. Shore N. Berger E. Small E. Penson D. et al. (2010 a) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422.
112. Kantoff P. Schuetz T. Blumenstein B. Glode L. Bilhartz D. Wyand M. et al. (2010 b) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099–1105.
113. Kao C. Wurz G. Lin Y. Vang D. Griffey S. Wolf M. et al. (2015) Assessing the effects of concurrent versus sequential cisplatin / radiotherapy on immune status in lung tumor-bearing C57BL/6 mice. Cancer Immunol Res 3: 741–750.
114. Kao C. Wurz G. Monjazeb A. Vang D. Cadman T. Griffey S. et al. (2014) Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC 1 transgenic lung cancer mouse model. Cancer Immunol Res 2: 581–589.
115. Kaplan D. Shankaran V. Dighe A. Stockert E. Aguet M. Old L. et al. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95: 7556–7561.
116. Kaufman H. Hamid O. D'Angelo S. Yuan G. Chin K. Bhatia S. et al. (2015) A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma. J Clin Oncol 33(Suppl.): abstract TPS9086.
117. Kawai T. Enomoto Y. Morikawa T. Matsushita H. Kume H. Fukayama M. et al. (2014) High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Mol Clin Oncol 2: 38–42.
118. Kelly K. Patel M. Infante J. Iannotti N. Nikolinakos P. Leach J. et al. (2015) Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. J Clin Oncol 33(Suppl.): abstract 3044.
119. Kenter G. Welters M. Valentijn A. Lowik M. Berends-van der Meer D. Vloon A. et al. (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361: 1838–1847.
120. Kimura T. Finn O. (2013) MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 13: 35–49.
121. Kirkwood J. Butterfield L. Tarhini A. Zarour H. Kalinski P. Ferrone S. (2012) Immunotherapy of cancer in 2012. CA Cancer J Clin 62: 309–335.
122. Klein G. Sjogren H. Klein E. Hellstrom K. (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20: 1561–1572.
123. Klein O. Davis I. McArthur G. Chen L. Haydon A. Parente P. et al. (2015) Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. Cancer Immunol Immunother 64: 507–518.
124. Kohrt H. Houot R. Marabelle A. Cho H. Osman K. Goldstein M. et al. (2012) Combination strategies to enhance antitumor ADCC. Immunotherapy 4: 511–527.
125. Kohrt H. Thielens A. Marabelle A. Sagiv-Barfi I. Sola C. Chanuc F. et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123: 678–686.
126. Kruit W. Suciu S. Dreno B. Mortier L. Robert C. Chiarion-Sileni V. et al. (2013) Selection of immunostimulant AS 15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 31: 2413–2420.
127. Kular R. Yehiely F. Deiss L. (2010) Rational drug design: a GAGE derived peptide kills tumor cells. Cancer Biol Ther 9: 825–831.
128. Larkin J. Chiarion-Sileni V. Gonzalez R. Grob J. Cowey C. Lao C. et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23–34.
129. Le Mercier I. Chen W. Lines J. Day M. Li J. Sergent P. et al. (2014) VISTA Regulates the development of protective antitumor immunity. Cancer Res 74: 1933–1944.
130. Lee H. Kim J. Cho S. Ko T. Kim H. Park S. et al. (2014) Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer. Korean J Thorac Cardiovasc Surg 47: 378–383.
131. Lee S. Chow L. (2014) A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736. Transl Lung Cancer Res 3: 408–410.
132. Lennerz V. Gross S. Gallerani E. Sessa C. Mach N. Boehm S. et al. (2014) Immunologic response to the survivin-derived multi-epitope vaccine EMD 640744 in patients with advanced solid tumors. Cancer Immunol Immunother 63: 381–394.
133. Lindauer M. Hochhaus A. (2014) Dasatinib. Recent Results Cancer Res 201: 27–65.
134. Lines J. Pantazi E. Mak J. Sempere L. Wang L. O'Connell S. et al. (2014 a) VISTA is an immune checkpoint molecule for human T cells. Cancer Res 74: 1924–1932.
135. Lines J. Sempere L. Broughton T. Wang L. Noelle R. (2014 b) VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2: 510–517.
136. Liu J. Yuan Y. Chen W. Putra J. Suriawinata A. Schenk A. et al. (2015 a) Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A 112: 6682–6687.
137. Liu S. Powderly J. Camidge D. Ready N. Heist R. Hodi S. et al. (2015 b) Safety and efficacy of MPDL3280A (anti-PD-L1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 33(Suppl.): abstract 8030.
138. Loke J. Khan J. Wilson J. Craddock C. Wheatley K. (2015) Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 94: 361–373.
139. Lu J. Lee-Gabel L. Nadeau M. Ferencz T. Soefje S. (2014) Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract. DOI: 10.1177/1078155214538087.
140. Manzoni M. Rovati B. Ronzoni M. Loupakis F. Mariucci S. Ricci V. et al. (2010) Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 79: 187–196.
141. Melero I. Gaudernack G. Gerritsen W. Huber C. Parmiani G. Scholl S. et al. (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11: 509–524.
142. Miles D. Roche H. Martin M. Perren T. Cameron D. Glaspy J. et al. (2011) Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16: 1092–1100.
143. Miller K. Wang M. Gralow J. Dickler M. Cobleigh M. Perez E. et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666–2676.
144. Mirandola L. Figueroa J. Phan T. Grizzi F. Kim M. Rahman R. et al. (2015) Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets. Oncotarget 6: 2812–2826.
145. Mitchell P. Thatcher N. Socinski M. Wasilewska-Tesluk E. Horwood K. Szczesna A. et al. (2015) Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 26: 1134–1142.
146. Miyazaki T. Ikeda K. Horie-Inoue K. Kondo T. Takahashi S. Inoue S. (2014) EBAG9 modulates host immune defense against tumor formation and metastasis by regulating cytotoxic activity of T lymphocytes. Oncogenesis 3: e126.
147. Mobahat M. Narendran A. Riabowol K. (2014) Survivin as a preferential target for cancer therapy. Int J Mol Sci 15: 2494–2516.
148. Morgan R. Chinnasamy N. Abate-Daga D. Gros A. Robbins P. Zheng Z. et al. (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36: 133–151.
149. Morse M. Chaudhry A. Gabitzsch E. Hobeika A. Osada T. Clay T. et al. (2013 a) Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 62: 1293–1301.
150. Morse M. Niedzwiecki D. Marshall J. Garrett C. Chang D. Aklilu M. et al. (2013 b) A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC 1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258: 879–886.
151. Muhlbauer M. Fleck M. Schutz C. Weiss T. Froh M. Blank C. et al. (2006) PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 45: 520–528.
152. Mullard A. (2013) New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 12: 489–492.
153. Nauts H. Fowler G. Bogatko F. (1953) A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl 276: 1–103.
154. Neninger Vinageras E. de la Torre A. Osorio Rodriguez M. Catala Ferrer M. Bravo I. Mendoza del Pino M. et al. (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26: 1452–1458.
155. Ngiow S. von Scheidt B. Akiba H. Yagita H. Teng M. Smyth M. (2011) Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 71: 3540–3551.
156. Nguyen L. Ohashi P. (2015) Clinical blockade of PD 1 and LAG3–potential mechanisms of action. Nat Rev Immunol 15: 45–56.
157. Nicholaou T. Ebert L. Davis I. Robson N. Klein O. Maraskovsky E. et al. (2006) Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 84: 303–317.
158. Nicholaou T. Ebert L. Davis I. McArthur G. Jackson H. Dimopoulos N. et al. (2009) Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 15: 2166–2173.
159. Nieto M. Cano A. (2012) The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 22: 361–368.
160. O'Sullivan C. Connolly R. (2014) Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer. Oncology (Williston Park) 28: 186–194.
161. Odunsi K. Matsuzaki J. Karbach J. Neumann A. Mhawech-Fauceglia P. Miller A. et al. (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109: 5797–5802.
162. Ofuji K. Tada Y. Yoshikawa T. Shimomura M. Yoshimura M. Saito K. et al. (2015) A peptide antigen derived from EGFR T790M is immunogenic in nonsmall cell lung cancer. Int J Oncol 46: 497–504.
163. Okabayashi K. Fujita T. Miyazaki J. Okada T. Iwata T. Hirao N. et al. (2012) Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. Cancer Sci 103: 1617–1624.
164. Okada H. Butterfield L. Hamilton R. Hoji A. Sakaki M. Ahn B. et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21: 286–294.
165. Ostendorf B. Le Coutre P. Kim T. Quintas-Cardama A. (2014) Nilotinib. Recent Results Cancer Res 201: 67–80.
166. Pao W. Miller V. Politi K. Riely G. Somwar R. Zakowski M. et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
167. Paz-Ares L. Mezger J. Ciuleanu T. Fischer J. von Pawel J. Provencio M. et al. (2015) Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 16: 328–337.
168. Perez E. Romond E. Suman V. Jeong J. Davidson N. Geyer C. Jr. et al. (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N 9831 and NSABP B-31. J Clin Oncol 29: 3366–3373.
169. Perez E. Romond E. Suman V. Jeong J. Sledge G. Geyer C. Jr. et al. (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744–3752.
170. Petrylak D. Powles T. Bellmunt J. Braiteh F. Loriot Y. Zambrano C. et al. (2015) A phase Ia study of MPDL3280A (anti-PD-L1): updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 33(Suppl.): abstract 4501.
171. Pinna A. (2014) Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28: 455–474.
172. Planchard D. Shtivelband M. Shi K. Ibrahim R. Ballas M. Sorio J. et al. (2015) A phase III study of MEDI 4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC). J Clin Oncol 33(Suppl.): abstract TPS8104.
173. Pollack I. Jakacki R. Butterfield L. Hamilton R. Panigrahy A. Potter D. et al. (2014) Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol 32: 2050–2058.
174. Postow M. Chesney J. Pavlick A. Robert C. Grossmann K. McDermott D. et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372: 2006–2017.
175. Powles T. Eder J. Fine G. Braiteh F. Loriot Y. Cruz C. et al. (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558–562.
176. Prehn R. Main J. (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769–778.
177. Price T. Peeters M. Kim T. Li J. Cascinu S. Ruff P. et al. (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15: 569–579.
178. Pujade-Lauraine E. Hilpert F. Weber B. Reuss A. Poveda A. Kristensen G. et al. (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32: 1302–1308.
179. Pujol J. Pirker R. Lynch T. Butts C. Rosell R. Shepherd F. et al. (2014) Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 83: 211–218.
180. Raetz E. Cairo M. Borowitz M. Blaney S. Krailo M. Leil T. et al. (2008) Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 26: 3756–3762.
181. Raetz E. Cairo M. Borowitz M. Lu X. Devidas M. Reid J. et al. (2015) Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer 62: 1171–1175.
182. Reardon D. Dietrich J. Kaley T. Gan H. Dunn G. Cloughesy T. et al. (2015) Phase II study to evaluate the clinical efficacy and safety of MEDI 4736 in patients with glioblastoma (GBM). J Clin Oncol 33(Suppl.): abstract TPS2077.
183. Reinhard H. Yousef S. Luetkens T. Fehse B. Berdien B. Kroger N. et al. (2014) Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. Blood Cancer J 4: e212.
184. Ribas A. Kefford R. Marshall M. Punt C. Haanen J. Marmol M. et al. (2013) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31: 616–622.
185. Robbins P. Morgan R. Feldman S. Yang J. Sherry R. Dudley M. et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917–924.
186. Robert C. Long G. Brady B. Dutriaux C. Maio M. Mortier L. et al. (2015 a) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320–330.
187. Robert C. Ribas A. Wolchok J. Hodi F. Hamid O. Kefford R. et al. (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384: 1109–1117.
188. Robert C. Schachter J. Long G. Arance A. Grob J. Mortier L. et al. (2015 b) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521–2532.
189. Robert C. Thomas L. Bondarenko I. O'Day S. Weber J. Garbe C. et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517–2526.
190. Romano E. Michielin O. Voelter V. Laurent J. Bichat H. Stravodimou A. et al. (2014) MART-1 peptide vaccination plus IMP 321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial. J Transl Med 12: 97.
191. Romond E. Perez E. Bryant J. Suman V. Geyer C. Jr. Davidson N. et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.
192. Rosenberg S. (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380–384.
193. Rowe J. Cen P. (2014) TroVax in colorectal cancer. Hum Vaccin Immunother 10: 3196–3200.
194. Ruiz R. Hunis B. Raez L. (2014) Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr Oncol Rep 16: 400.
195. Saadatmand S. de Kruijf E. Sajet A. Dekker-Ensink N. van Nes J. Putter H. et al. (2013) Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg 100: 252–260.
196. Sakuishi K. Apetoh L. Sullivan J. Blazar B. Kuchroo V. Anderson A. (2010) Targeting tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 207: 2187–2194.
197. Saltz L. Meropol N. Loehrer P. Needle M. Sr. Kopit J. Mayer R. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208.
198. Sandler A. Gray R. Perry M. Brahmer J. Schiller J. Dowlati A. et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550.
199. Sapra P. Damelin M. Dijoseph J. Marquette K. Geles K. Golas J. et al. (2013) Long-term tumor regression induced by an antibody–drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 12: 38–47.
200. Savage P. Leventhal D. Malchow S. (2014) Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev 259: 245–258.
201. Sawada Y. Komori H. Tsunoda Y. Shimomura M. Takahashi M. Baba H. et al. (2014) Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncol Rep 31: 1051–1058.
202. Scagliotti G. Novello S. Schiller J. Hirsh V. Sequist L. Soria J. et al. (2012) Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 13: 391–395.
203. Schreiber R. Old L. Smyth M. (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565–1570.
204. Schumacher T. Bunse L. Pusch S. Sahm F. Wiestler B. Quandt J. et al. (2014) A vaccine targeting mutant IDH 1 induces antitumour immunity. Nature 512: 324–327.
205. Schwartzentruber D. Lawson D. Richards J. Conry R. Miller D. Treisman J. et al. (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364: 2119–2127.
206. Scott L. (2015) Nivolumab: a review in advanced melanoma. Drugs 75: 1413–1424.
207. Seimetz D. (2011) Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2: 309–316.
208. Shabani M. Naseri J. Shokri F. (2015) Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy. Expert Opin Ther Targets 19: 941–955.
209. Shankaran V. Ikeda H. Bruce A. White J. Swanson P. Old L. et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107–1111.
210. Shaw D. Connolly N. Patel P. Kilany S. Hedlund G. Nordle O. et al. (2007) A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer 96: 567–574.
211. Shore N. (2014) PROSTVAC(R) targeted immunotherapy candidate for prostate cancer. Immunotherapy 6: 235–247.
212. Sierro S. Romero P. Speiser D. (2011) The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 15: 91–101.
213. Singh P. Pal S. Alex A. Agarwal N. (2015) Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol 11: 2137–2148.
214. Skoetz N. Bauer K. Elter T. Monsef I. Roloff V. Hallek M. et al. (2012) Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev 2: CD008078.
215. Slamon D. Clark G. Wong S. Levin W. Ullrich A. McGuire W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
216. Slamon D. Godolphin W. Jones L. Holt J. Wong S. Keith D. et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712.
217. Slamon D. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bajamonde A. et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
218. Sliwkowski M. Mellman I. (2013) Antibody therapeutics in cancer. Science 341: 1192–1198.
219. Smith H. Cronk R. Lang J. McNeel D. (2011) Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer. Cancer Res 71: 6785–6795.
220. Sobrero A. Maurel J. Fehrenbacher L. Scheithauer W. Abubakr Y. Lutz M. et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311–2319.
221. Soliman H. Jackson E. Neuger T. Dees E. Harvey R. Han H. et al. (2014) A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 5: 8136–8146.
222. Southall P. Boxer G. Bagshawe K. Hole N. Bromley M. Stern P. (1990) Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61: 89–95.
223. Spigel D. Chaft J. Gettinger S. Chao B. Dirix L. Schmid P. et al. (2015) Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PD-L1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol 33(Suppl.): abstract 8028.
224. Spigel D. Ervin T. Ramlau R. Daniel D. Goldschmidt J. Jr. Blumenschein G. Jr. et al. (2013) Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31: 4105–4114.
225. Spira A. Park K. Mazieres J. Vansteenkiste J. Rittmeyer A. Ballinger M. et al. (2015) Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A versus docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol 33(Suppl.): abstract 8010.
226. Staff C. Mozaffari F. Frodin J. Mellstedt H. Liljefors M. (2014) Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int J Oncol 45: 1293–1303.
227. Stagg J. Loi S. Divisekera U. Ngiow S. Duret H. Yagita H. et al. (2011) Anti-ErbB-2 m Ab therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 m Ab therapy. Proc Natl Acad Sci U S A 108: 7142–7147.
228. Stern P. Brazzatti J. Sawan S. McGinn O. (2014) Understanding and exploiting 5T4 oncofoetal glycoprotein expression. Semin Cancer Biol 29: 13–20.
229. Stinchcombe T. (2014) Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 6: 240–253.
230. Sunshine J. Taube J. (2015) PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 23: 32–38.
231. Suzuki M. Cheung N. (2015) Disialoganglioside GD 2 as a therapeutic target for human diseases. Expert Opin Ther Targets 19: 349–362.
232. Swaika A. Hammond W. Joseph R. (2015) Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol 67: 4–17.
233. Szabo E. (2003) MUC1 expression in lung cancer. Methods Mol Med 74: 251–258.
234. Tarhini A. Leng S. Moschos S. Yin Y. Sander C. Lin Y. et al. (2012) Safety and immunogenicity of vaccination with MART-1 (26–35, 27L), gp 100 (209–217, 210M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 35: 359–366.
235. Terme M. Pernot S. Marcheteau E. Sandoval F. Benhamouda N. Colussi O. et al. (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 73: 539–549.
236. Tewari K. Sill M. Long H. 3rd Penson R. Huang H. Ramondetta L. et al. (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370: 734–743.
237. Thatcher N. Hirsch F. Luft A. Szczesna A. Ciuleanu T. Dediu M. et al. (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16: 763–774.
238. Topalian S. Hodi F. Brahmer J. Gettinger S. Smith D. McDermott D. et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443–2454.
239. Topalian S. Sznol M. McDermott D. Kluger H. Carvajal R. Sharfman W. et al. (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32: 1020–1030.
240. Torres M. Chakraborty S. Souchek J. Batra S. (2012) Mucin-based targeted pancreatic cancer therapy. Curr Pharm Des 18: 2472–2481.
241. Turriziani M. Fantini M. Benvenuto M. Izzi V. Masuelli L. Sacchetti P. et al. (2012) Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov 7: 265–296.
242. Ulloa-Montoya F. Louahed J. Dizier B. Gruselle O. Spiessens B. Lehmann F. et al. (2013) Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31: 2388–2395.
243. Uyttenhove C. Pilotte L. Theate I. Stroobant V. Colau D. Parmentier N. et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269–1274.
244. Vacchelli E. Aranda F. Eggermont A. Galon J. Sautes-Fridman C. Zitvogel L. et al. (2014) Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 3: e27048.
245. van Cutsem E. Kohne C. Hitre E. Zaluski J. Chang Chien C. Makhson A. et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408–1417.
246. van Cutsem E. Peeters M. Siena S. Humblet Y. Hendlisz A. Neyns B. et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664.
247. van der Bruggen P. Traversari C. Chomez P. Lurquin C. de Plaen E. van den Eynde B. et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647.
248. Vansteenkiste J. Zielinski M. Linder A. Dahabreh J. Gonzalez E. Malinowski W. et al. (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31: 2396–2403.
249. Veillette A. Guo H. (2013) CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88: 168–177.
250. Vermorken J. Mesia R. Rivera F. Remenar E. Kawecki A. Rottey S. et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116–1127.
251. Vermorken J. Trigo J. Hitt R. Koralewski P. Diaz-Rubio E. Rolland F. et al. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and / or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171–2177.
252. Vigneron N. Stroobant V. van den Eynde B. van der Bruggen P. (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13: 15.
253. Vlad A. Kettel J. Alajez N. Carlos C. Finn O. (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82: 249–293.
254. Waller C. (2014) Imatinib mesylate. Recent Results Cancer Res 201: 1–25.
255. Wang L. Rubinstein R. Lines J. Wasiuk A. Ahonen C. Guo Y. et al. (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208: 577–592.
256. Wang Y. Dong Q. Miao Y. Fu L. Lin X. Wang E. (2013) Clinical significance and biological roles of SPAG 9 overexpression in non-small cell lung cancer. Lung Cancer 81: 266–272.
257. Wehrle J. Pahl H. von Bubnoff N. (2014) Ponatinib: a third-generation inhibitor for the treatment of CML. Recent Results Cancer Res 201: 99–107.
258. Weiner L. Surana R. Wang S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317–327.
259. Whitehurst A. (2014) Cause and consequence of cancer / testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 54: 251–272.
260. Wilke H. Muro K. van Cutsem E. Oh S. Bodoky G. Shimada Y. et al. (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15: 1224–1235.
261. Wu J. Wei J. Meng K. Chen J. Gao W. Zhang J. et al. (2009) Identification of an HLA-A*0201-restrictive CTL epitope from MUC 4 for applicable vaccine therapy. Immunopharmacol Immunotoxicol 31: 468–476.
262. Wurz G. Kao C. Wolf M. de Gregorio M. (2014) Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother 10: 3383–3393.
263. Xie C. Wang G. (2015) XAGE-1b Cancer / Testis Antigen Is a Potential Target for Immunotherapy in Prostate Cancer. Urol Int 94: 354–362.
264. Yamada T. Azuma K. Muta E. Kim J. Sugawara S. Zhang G. et al. (2013) EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PloS ONE 8: e78389.
265. Yang Z. Grote D. Ziesmer S. Niki T. Hirashima M. Novak A. et al. (2012) IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 122: 1271–1282.
266. Yonezawa A. Dutt S. Chester C. Kim J. Kohrt H. (2015) Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res 21: 3113–3120.
267. Yoshitake Y. Fukuma D. Yuno A. Hirayama M. Nakayama H. Tanaka T. et al. (2015) Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 21: 312–321.
268. Zappasodi R. Bongarzone I. Ghedini G. Castagnoli L. Cabras A. Messina A. et al. (2011) Serological identification of HSP 105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 118: 4421–4430.
269. Zaravinos A. (2014) An updated overview of HPV-associated head and neck carcinomas. Oncotarget 5: 3956–3969.
270. Zhang L. Chen J. Song X. Wen W. Li Y. Zhang Y. et al. (2013) Cancer / testis antigen HCA587-derived long peptide vaccine generates potent immunologic responses and antitumor effects in mouse model. Oncol Res 21: 193–200.
271. Zhang Q. He S. Shen N. Luo B. Fan R. Fu J. et al. (2014) Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int J Clin Exp Pathol 7: 3918–3927.
272. Zhang R. Bines S. Ruby C. Kaufman H. (2012) TroVax((R)) vaccine therapy for renal cell carcinoma. Immunotherapy 4: 27–42.
273. Zhang S. Zhou X. Yu H. Yu Y. (2010) Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 10: 163.
274. Zhou Q. Guo A. Xu C. An S. Wang Z. Yang S. et al. (2008) A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol 153: 392–400.
275. Zhu C. Anderson A. Schubart A. Xiong H. Imitola J. Khoury S. et al. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6: 1245–1252.
276. Zhu Y. Zhang J. Liang W. Zhu R. Wang B. Miao Y. et al. (2014) Pancreatic cancer counterattack: MUC 4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte. Oncol Rep 31: 1768–1776.